<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26482128</article-id><article-id pub-id-type="pmc">4616250</article-id><article-id pub-id-type="publisher-id">1000</article-id><article-id pub-id-type="doi">10.1186/s13063-015-1000-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Screen-and-treat program by point-of-care of <italic>Atopobium vaginae</italic> and <italic>Gardnerella vaginalis</italic> in preventing preterm birth (AuTop trial): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bretelle</surname><given-names>Florence</given-names></name><address><email>florence.bretelle@ap-hm.fr</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Fenollar</surname><given-names>Florence</given-names></name><address><email>florence.fenollar@univ-amu.fr</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Baumstarck</surname><given-names>Karine</given-names></name><address><email>karine.baumstarck@ap-hm.fr</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Fortanier</surname><given-names>C&#x000e9;cile</given-names></name><address><email>cecile.fortanier@ap-hm.fr</email></address><xref ref-type="aff" rid="Aff5"/></contrib><contrib contrib-type="author"><name><surname>Cocallemen</surname><given-names>Jean Fran&#x000e7;ois</given-names></name><address><email>jean-francois.cocallemen@ap-hm.fr</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Serazin</surname><given-names>Val&#x000e9;rie</given-names></name><address><email>vserazin@chi-poissy-st-germain.fr</email></address><xref ref-type="aff" rid="Aff6"/><xref ref-type="aff" rid="Aff7"/></contrib><contrib contrib-type="author"><name><surname>Raoult</surname><given-names>Didier</given-names></name><address><email>didier.raoult@univ-amu.fr</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Auquier</surname><given-names>Pascal</given-names></name><address><email>pascal.auquier@univ-amu.fr</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Loubi&#x000e8;re</surname><given-names>Sandrine</given-names></name><address><email>sandrine.loubiere@univ-amu.fr</email></address><xref ref-type="aff" rid="Aff3"/><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Department of Gynaecology and Obstetrics, Gyn&#x000e9;pole, Marseille, Pr Boubli, H&#x000f4;pital Nord, Assistance Publique-H&#x000f4;pitaux de Marseille (AP-HM), Aix- Marseille Universit&#x000e9;, Marseille, France </aff><aff id="Aff2"><label/>Aix-Marseille Universit&#x000e9;, Unit&#x000e9; de Recherche sur les Maladies Infectieuses Tropicales et Emergentes, UM63, CNRS 7278, IRD 198, INSERM 1095, Marseille, France </aff><aff id="Aff3"><label/>EA3279 Self-perceived Health Assessment Research Unit and Department of Public Health, AP-HM, Aix-Marseille University, Marseille, France </aff><aff id="Aff4"><label/>Department of Research and Innovation, Support Unit for clinical research and economic evaluation, Assistance Publique - H&#x000f4;pitaux de Marseille, Marseille, 13385 France </aff><aff id="Aff5"><label/>H&#x000f4;pital Sainte Marguerite, Assistance Publique - H&#x000f4;pitaux de Marseille, Marseille cedex 9, France </aff><aff id="Aff6"><label/>Service de biologie m&#x000e9;dicale, CHI Poissy-Saint Germain, Poissy, Cedex France </aff><aff id="Aff7"><label/>EA 2493, UFR des sciences de la sant&#x000e9;, 78180 Montigny-Le-Bretonneux, France </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>470</elocation-id><history><date date-type="received"><day>11</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>6</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Bretelle et al. 2015</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>International recommendations in favor of screening for vaginal infection in pregnancy are based on heterogeneous criteria. In most developed countries, the diagnosis of bacterial vaginosis is only recommended for women with high-risk of preterm birth. The Nugent score is currently used, but molecular quantification tools have recently been reported with a high sensitivity and specificity. Their value for reducing preterm birth rates and related complications remains unexplored. This trial was designed to assess the cost-effectiveness of a systematic screen-and-treat program based on a point-of-care technique for rapid molecular diagnosis, immediately followed by an appropriate antibiotic treatment, to detect the presence of abnormal vaginal flora (specifically, <italic>Atopobium vaginae</italic> and <italic>Gardnerella vaginalis</italic>) before 20&#x000a0;weeks of gestation in pregnant women in France. We hypothesized that this program would translate into significant reductions in both the rate of preterm births and the medical costs associated with preterm birth.</p></sec><sec><title>Methods/Design</title><p>A multicenter, open-label randomized controlled trial (RCT) will be conducted in which 20 French obstetrics and gynecology centers will recruit eligible pregnant women at less than 20&#x000a0;weeks gestation with singleton pregnancy and with a low-risk factor for preterm birth. Interventions will include a) an experimental group that will receive a systematic rapid screen-and-treat program from a point-of-care analysis using a molecular quantification method and b) a control group that will receive usual care management. Randomization will be in a 1:1 allocation ratio. The primary endpoint that will be assessed over a period of 12&#x000a0;months will be the incremental cost-effectiveness ratio (ICER) expressed as cost per avoided preterm birth before 37&#x000a0;weeks. Secondary endpoints will include ICER per avoided preterm birth before 24, 28 and 32&#x000a0;weeks, obstetrical outcomes, neonatal outcomes, rates of treatment failure and recurrence episodes for positive women. Uncertainty surrounding these estimates will be addressed using nonparametric bootstrapping and represented using cost-effectiveness acceptability curves. A total of 6,800 pregnant women will be included.</p></sec><sec><title>Discussion</title><p>This appropriate randomized controlled design will provide insight into the cost-effectiveness and therefore the potential cost savings of a rapid screen-and-treat strategy for molecular abnormal vaginal flora in pregnant women. National and international recommendations could be updated based on the findings of this study.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02288832?term=NCT02288832amp;rank=1">NCT02288832</ext-link> (registration date: 30 October 2014); Eudract: 2014-001559-22.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Pregnancy</kwd><kwd>bacterial vaginosis</kwd><kwd>preterm birth</kwd><kwd>screen-and-treat strategy</kwd><kwd>cost-effectiveness analysis</kwd><kwd>point-of-care</kwd><kwd>molecular diagnosis</kwd><kwd>antibiotic treatment</kwd><kwd>randomized controlled trial</kwd><kwd><italic>Atopobium vaginae</italic></kwd><kwd><italic>Gardnerella vaginalis</italic></kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Prematurity is an important cause of death and disabilities of infants and children [<xref ref-type="bibr" rid="CR1">1</xref>]. The preterm birth rate was approximately 7.4&#x000a0;% in France in 2010 [<xref ref-type="bibr" rid="CR2">2</xref>], as observed in other developed countries [<xref ref-type="bibr" rid="CR3">3</xref>]. The presence of infection and/or inflammation during pregnancy is notably known as a major risk factor for spontaneous preterm birth [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. Pregnant women with bacterial vaginosis (BV) have an increased risk of preterm birth compared to women without BV, and the risk of preterm birth is higher if BV occurs in the early stage of pregnancy [<xref ref-type="bibr" rid="CR5">5</xref>]. Several bacteria are associated with the diagnosis of BV [<xref ref-type="bibr" rid="CR7">7</xref>]. However, BV is always associated with the presence of high loads of <italic>Atopobium vaginae</italic> and/or <italic>Gardnerella vaginalis</italic> [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Our team previously showed that high vaginal concentrations of <italic>A. vaginae</italic> and/or <italic>G. vaginalis</italic> were associated with a significantly decreased interval between preterm labor and delivery in high-risk pregnancies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Therefore, the control of vaginal flora anomalies (especially <italic>A. vaginae</italic> and/or <italic>G. vaginalis</italic>) in low-risk populations should be considered as an important aim, to see whether their treatments might prevent preterm birth.</p><p>In France, the screening (and treatment) of BV is only recommended for women with high-risk of preterm birth [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. Because BV is asymptomatic in approximately 50&#x000a0;% of cases [<xref ref-type="bibr" rid="CR14">14</xref>] and early vaginal infection during pregnancy induces higher risk of obstetrical complications, one of the measures to prevent preterm birth should concern a systematic screen-and-treat strategy at the first stage of pregnancy. The standard diagnostic test is the Nugent score [<xref ref-type="bibr" rid="CR13">13</xref>], which is laborious and not easily reproducible [<xref ref-type="bibr" rid="CR9">9</xref>]. Such abnormalities have led some authors to propose new diagnostic tools based on molecular biological techniques [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. The molecular approach based on the quantitative real-time polymerase chain reaction (qPCR) assay appears to be more reproducible and reclassifies a large number of flora rated as intermediate or normal on the Nugent score as true BV [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>Answering cost-effectiveness questions is a critical step in the translation of technological innovation findings into decision making at the public policy level. Although there is a considerable amount of literature on the economic consequences of preterm birth, little is known about the cost-effectiveness of screen-and-treat strategies for vaginal infection. To date, only one cost-effectiveness analysis of a simple screen-and-treat program for common asymptomatic vaginal infections in pregnancy has been published [<xref ref-type="bibr" rid="CR18">18</xref>]: it showed cost savings through the first 6&#x000a0;years of life. In this study, the women were tested with a vaginal Gram stain and scoring criteria by the Nugent technique, which does not identify the morphotypes associated with BV such as <italic>A. vaginae,</italic> and the screening was performed in the second trimester of pregnancy, which is probably too late to prevent pregnancy complications.</p><p>All these considerations may lead to questions on the cost effectiveness of a systematic screen-and-treat program during the first trimester for flora vaginal anomalies among pregnant women with a low-risk of preterm birth, taking into account advances in diagnostic tools, bacteria species targeted and antibacterial treatments. For this purpose, a multicenter, randomized controlled study was designated to assess the cost effectiveness of the innovative screening for <italic>A. vaginae</italic> and <italic>G. vaginalis</italic> vaginal portage using a molecular quantification method by point-of-care with an appropriate treatment for positive cases, compared to a usual care strategy in pregnant women at less than 20&#x000a0;weeks of gestation. Several obstetrical and neonatal secondary outcomes are also considered, as well as rates of treatment failure and recurrence episodes.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods/Design</title><sec id="Sec3"><title>Design</title><p>A multicenter, open-label randomized controlled, two-parallel group study was designed in which pregnant women who attend prenatal care consultations before 20&#x000a0;weeks&#x02019; gestation at French obstetrics and gynecology centers are randomized between two management strategies: a systematic vaginosis screen-and-treat strategy (experimental group) and usual care management (control group). The study protocol was designed using the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement and according to the guidelines of cost-effectiveness studies of the French Health Authority [Haute Autorit&#x000e9; en Sant&#x000e9;, Choix m&#x000e9;thodologiques pour l&#x02019;&#x000e9;valuation &#x000e9;conomique &#x000e0; la HAS <ext-link ext-link-type="uri" xlink:href="http://www.has-sante.fr/portail/jcms/c_1120711/choix-methodologiques-pour-l-evaluation-economique-a-la-has">http://www.has-sante.fr/portail/jcms/c_1120711/choix-methodologiques-pour-l-evaluation-economique-a-la-has</ext-link>]. Timing and phasing after eligibility checks are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Schema of timing and phasing - AuTop Study</p></caption><graphic xlink:href="13063_2015_1000_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec4"><title>Partners</title><p>This work is supported by an institutional grant from the French 2014 National Program of Cost-effectiveness Research (Programme de Recherche M&#x000e9;dico-Economique, FINESS number 130789049). The recruiting will take place in 20 French obstetrics and gynecology centers. The molecular analyses will be performed in two point-of-care laboratories. The methodological support will be provided by the Clinical and Cost-Effectiveness Research Unit (Assistance Publique - H&#x000f4;pitaux de Marseille, AP-HM, France), and the Clinical Investigation Unit (Centre d&#x02019;Investigation Clinique, AP-HM, France). The central pharmacy of AP-HM is in charge of the assignment, allocation and delivery of the devices. All the details are provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>French partners</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Gynecologists</td><td>Center/department</td></tr><tr><td>&#x02003;Pr Florence Bretelle</td><td>Coordinating investigator. Public academic teaching hospital Nord, Marseille</td></tr><tr><td>&#x02003;Dr H&#x000e9;l&#x000e8;ne Heckenroth</td><td>Public academic teaching hospital La Conception, Marseille</td></tr><tr><td>&#x02003;Dr Raoul Desbriere</td><td>Private Hospital Saint Joseph, Marseille</td></tr><tr><td>&#x02003;Dr Nadia Slim</td><td>Private Hospital Bouchard, Marseille</td></tr><tr><td>&#x02003;Dr Nawal Chenni-Asselah</td><td>Public hospital, Aubagne</td></tr><tr><td>&#x02003;Dr Xavier Danoy</td><td>Public academic hospital, Aix-en-Provence</td></tr><tr><td>&#x02003;Dr Franck Mauviel</td><td>Public academic hospital, Toulon Sainte Musse</td></tr><tr><td>&#x02003;Pr Andr&#x000e9; Bongain</td><td>Public academic teaching hospital, Nice</td></tr><tr><td>&#x02003;Pr Pierre Mares</td><td>Public academic teaching hospital, Caremeau</td></tr><tr><td>&#x02003;Pr Patrick Rozenberg</td><td>Public academic hospital, Poissy-Saint-Germain</td></tr><tr><td>&#x02003;Dr Thomas Schmitz</td><td>Public academic teaching hospital Robert Debr&#x000e9;, Paris</td></tr><tr><td>&#x02003;Pr Alexandra Benachi</td><td>Public academic teaching hospital Antoine B&#x000e9;cl&#x000e8;re, Clamart</td></tr><tr><td>&#x02003;Pr Marie-Victoire Senat</td><td>Public academic teaching hospital Kremlin-Bic&#x000ea;tre, Kremlin-Bic&#x000ea;tre</td></tr><tr><td>&#x02003;Pr Bassam Haddad</td><td>Public academic hospital, Cr&#x000e9;teil</td></tr><tr><td>&#x02003;Dr Jean-Pierre M&#x000e9;nard</td><td>Protection Maternelle Infantile, Val de Marne</td></tr><tr><td>&#x02003;Pr Gilles Kayem</td><td>Public academic teaching hospital Armand Trousseau, Paris</td></tr><tr><td>&#x02003;Pr Loic Sentilhes</td><td>Public academic teaching hospital, Angers</td></tr><tr><td>&#x02003;Pr C&#x000e9;line Chauleur</td><td>Public academic teaching hospital, Saint-Etienne</td></tr><tr><td>&#x02003;Dr Jean-Luc Volumenie</td><td>Public academic teaching hospital, Martinique</td></tr><tr><td>&#x02003;Dr Philippe Kadhel</td><td>Public academic teaching hospital, Pointe-&#x000e0;-Pitre</td></tr><tr><td>Clinical microbiologists</td><td>Center/department</td></tr><tr><td>&#x02003;Pr Florence Fenollar</td><td>F&#x000e9;d&#x000e9;ration de Microbiologie Clinique. Public academic teaching hospital la Timone, Marseille</td></tr><tr><td>&#x02003;Dr Val&#x000e9;rie Serazin</td><td>Service de Biologie M&#x000e9;dicale - UF de Biologie mol&#x000e9;culaire. Public general hospital, CHI Poissy St Germain</td></tr><tr><td>Methodology team</td><td>Center/department</td></tr><tr><td>&#x02003;Pr Pascal Auquier</td><td>Public health, public academic teaching hospital, Marseille</td></tr><tr><td>&#x02003;Sandrine Loubi&#x000e8;re &#x00026; C&#x000e9;cile Fortanier</td><td>Health economy, public academic teaching hospital, Marseille</td></tr><tr><td>&#x02003;Dr Karine Baumstarck</td><td>Clinical research unit, public academic teaching hospital, Marseille</td></tr><tr><td>&#x02003;Dr Nathalie Lesavre</td><td>Clinical investigation center, public academic teaching hospital, Marseille</td></tr><tr><td>&#x02003;Dr St&#x000e9;phane Honor&#x000e9; &#x00026; Dr Anita Cohen</td><td>P&#x000f4;le Pharmacie, public academic teaching hospital, Marseille</td></tr></tbody></table></table-wrap></p><sec id="Sec5"><title>Inclusion and exclusion criteria</title><p>The details of the inclusion and exclusion criteria are provided in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. The main inclusion criteria are that women must have less than 20&#x000a0;weeks of gestation, with singleton pregnancy, they must be symptomatic or nonsymptomatic with regard to their diagnosis of BV, and they must not have high-risk factors of preterm birth. The main exclusion criteria are having known conditions at the time of recruitment that have either increased risk of spontaneous preterm birth (previous preterm birth, uterine malformation, or multiple pregnancy) or that may need preterm delivery due to medical indication: hypertension, diabetes, fetal malformation, increased risk for preeclampsia (or other conditions that the investigators may consider).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Selection criteria</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>Inclusion criteria</td></tr><tr><td>&#x02003;Woman&#x02009;&#x02265;&#x02009;18&#x000a0;years of age</td></tr><tr><td>&#x02003;Woman less than 20&#x000a0;weeks of gestation</td></tr><tr><td>&#x02003;Woman with singleton pregnancy</td></tr><tr><td>&#x02003;Woman without history of preterm birth or late miscarriage</td></tr><tr><td>&#x02003;Woman with low-risk factor of preterm birth (absence of diabetes, systemic lupus erythematosus, treated hypertension, fetal malformation, cervical conization, or multiple pregnancy)</td></tr><tr><td>&#x02003;Woman affiliated to or beneficiary of a social security system</td></tr><tr><td>&#x02003;Woman who have signed written informed consent</td></tr><tr><td>Exclusion criteria</td></tr><tr><td>&#x02003;Woman more than 20&#x000a0;weeks of gestation</td></tr><tr><td>&#x02003;Minor woman or woman deprived of their freedom by a court/administrative decision or woman under legal protection</td></tr><tr><td>&#x02003;Woman who present high-risk factor of preterm birth or late miscarriage</td></tr><tr><td>&#x02003;Woman with extrauterine pregnancy</td></tr><tr><td>&#x02003;Woman with non-evolutive pregnancy</td></tr><tr><td>&#x02003;Woman who have received antibiotic treatment in the week before inclusion</td></tr><tr><td>&#x02003;Woman misunderstanding the written and spoken French language</td></tr><tr><td>&#x02003;Subject participating in another biomedical research protocol</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec6"><title>Interventions</title><sec id="Sec7"><title>Experimental group: screen-and-treat strategy</title><p>Pregnant women assigned to the intervention group are asked for a self-collected vaginal swab at randomization (Time 0). The self-collected vaginal swab has previously been demonstrated to have high validity and reliability compared to a practitioner-collected swab [<xref ref-type="bibr" rid="CR17">17</xref>]. The swab will be immediately tested for <italic>A. vaginae</italic> and <italic>G. vaginalis</italic> using a systematic point-of-care screening test. Quantitative molecular analyses will be performed in laboratories that have experienced and national accreditation to realize point-of-care techniques. The quantitative real-time PCR (qPCR) method used to diagnose BV was previously described [<xref ref-type="bibr" rid="CR11">11</xref>]. The result is reported as copies of microorganism DNA per 1&#x000a0;mL of vaginal suspension [<xref ref-type="bibr" rid="CR9">9</xref>]. According to previous works [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], BV will be defined by an <italic>A. vaginae</italic> load &#x02265;&#x02009;10<sup>8</sup> copies/mL and/or a <italic>G. vaginalis</italic> load &#x02265;&#x02009;10<sup>9</sup> copies/mL. The conclusion will be feedback of the positive or negative test result to the practitioner within less than 24&#x000a0;hours. In cases of positive diagnosis, the pregnant woman will be referred to an obstetrician, and an appropriate antibiotic treatment will be provided. The first intention for treatment of <italic>A. vaginae</italic> and <italic>G. vaginalis</italic> will be azithromycin (single dose, 1&#x000a0;g at day 1 and 1&#x000a0;g at day 3). The second choice for antibiotic treatment will be amoxicillin 2&#x000a0;g per day during 7&#x000a0;days in cases of known intolerance of azithromicin. The following procedure for women who are diagnosed positive is to perform a series of three successive screening controls until 28&#x000a0;weeks to detect either the failure of antibiotic treatment or a recurrence (that is, reappearance of bacteria from a control vaginal swab after therapy is stopped) (see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). In cases of recurrence or treatment failure, a new antibiotic treatment will be provided, based on protocol guidelines (see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). For women with a first negative diagnosis, the usual care management will be proposed.<fig id="Fig2"><label>Fig. 2</label><caption><p>Schema of treatment algorithm alongside the trial - AuTop Study</p></caption><graphic xlink:href="13063_2015_1000_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec8"><title>Control group: usual care management</title><p>No systematic vaginosis screening will be performed on the women assigned to the control group according to national and international guidelines [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Usual pregnancy care includes 6 to 8 obstetrical consultations, no systematic vaginal swab, three ultrasound scans, 1st trimester Down syndrome screening and blood sampling for toxoplasmosis, syphilis, rubella, and complete blood group testing.</p></sec></sec><sec id="Sec9"><title>Recruitment</title><p>Eligible women will be invited to take part in the study during a routine prenatal consultation planned in the first trimester of their pregnancy. The women who meet all the inclusion criteria will be randomized into one of the two groups after completing the informed consent form.</p></sec><sec id="Sec10"><title>Randomization</title><p>Computer-generated randomized lists were drawn up before the beginning of the study, using a permuted block design, under the responsibility of the clinical research unit (AP-HM). The randomization was stratified by center (1:1 allocation ratio).</p></sec><sec id="Sec11"><title>Endpoints</title><sec id="Sec12"><title>Primary endpoint</title><p>The primary endpoint is the incremental cost-effectiveness ratio (ICER), expressed as the extra cost per additional preterm birth avoided before 37&#x000a0;weeks. The effectiveness criterion has been discussed and consensually approved by all the study&#x02019;s main partners (gynecologist coordinator and co-coordinators, biologists, health economist and methodologist). We can assume that this intermediary criterion properly reflects short- and long-term prognosis of the children [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec13"><title>Secondary endpoints</title><p>The secondary endpoints are as follows:<list list-type="order"><list-item><p>ICER per preterm birth avoided before 26, 28, 32 and 34&#x000a0;weeks.</p></list-item><list-item><p>Obstetrical outcomes: rates of preterm birth before 26, 28, 32, 34, and 37&#x000a0;weeks of gestation, spontaneous abortion (between 14-22 weeks), late miscarriage (between 22-24 weeks), premature rupture of membranes, severe intrauterine growth restriction, preterm labor, duration of the woman&#x02019;s hospitalization (that is hospitalization for delivery or preterm labor and potential previous hospitalizations due to gynecologic complications during pregnancy).</p></list-item><list-item><p>Neonatal outcomes: neonatal mortality, neonatal morbidity (respiratory distress syndrome, bronchopulmonary dysplasia, necrotizing enterocolitis, periventricular leukomalacia), transfer to a neonatal intensive care unit (duration), mechanical ventilation (duration), congenital anomalies and duration of the newborn&#x02019;s hospitalization.</p></list-item><list-item><p>Treatment effectiveness: rate of recurrence (defined as a positive control vaginal swab using qPCR after the negativation of a precedent control vaginal swab), rate of treatment failure (defined as <italic>A. vaginae</italic> &#x0003e;&#x02009;10<sup>8</sup> copies/mL and/or a <italic>G. vaginalis</italic> load &#x02265;&#x02009;10<sup>9</sup> copies/mL from a control vaginal swab) and side effects associated with treatment.</p></list-item><list-item><p>Other health care utilization: all the mother&#x02019;s use of health care during the whole study period (for example, gynecologists and general practitioner consultations, hospital admission, clinical examinations and medications), as well as health care for the newborn (including neonatal care, re-hospitalization, medications, planned and non-planned consultations with pediatric practitioner or other specialists).</p></list-item></list></p></sec></sec><sec id="Sec14"><title>Data collection and follow-up</title><p>All data will be recorded from an electronic case report form (eCRF) specifically elaborated for the study (eCRF CleanWEB, Telemedicine Technologies S.A.S., <ext-link ext-link-type="uri" xlink:href="http://www.tentelemed.com">www.tentelemed.com</ext-link>, 2015) and will be recorded at four specific study&#x02019;s times as follows: randomization (T0), baseline assessment (T1), delivery (T2), and at 6&#x000a0;months after delivery (T3). All assessments are based either on medical files (pregnancy and delivery characteristics, obstetrical and neonatal outcomes), face-to-face questionnaires (smoking and alcohol habits, personal hygiene, pregnancies history or symptoms, and concomitant treatments such as treatment with pessary or progesterone), phone calls (to collect data on vaginal symptoms or potential side-effects of antibiotic) or self-report (health outcomes of their infant and health service use during the 6&#x000a0;months following the initial hospitalization). Details of the data recorded at the different times of the study are given in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Data collection, instruments and assessment times</p></caption><table frame="hsides" rules="groups"><tbody><tr><td>At randomization (T0)</td><td>Data on the health status of the participant and pregnancy characteristics will be collected from medical files of the practitioners. A face-to-face questionnaire will be also completed by all women and filled out by the midwife/obstetrician to collect specific data on demographics characteristics, smoking and alcohol habits, previous pregnancies and personal hygiene. The first vaginal swab will be collected by the practitioner and send to one of the two point-of-care laboratories associated to the study.</td></tr><tr><td>At baseline assessment &#x02013; (during screening and treatment phases - T1)</td><td>Subsequent vaginal swabs will be realized during either routine pregnancy consultation or at the woman&#x02019;s home depending on each participant schedule. In this later case, the sample will be sent by the women to the referent POC laboratory using a stamped, self-addressed envelope. Symptoms and potential side effects of antibiotics will be collected via a telephone interview. Participants will be informed via a phone call for subsequent vaginal swabs and treatment intake if needed.</td></tr><tr><td>At delivery (T2)</td><td>All relevant clinical and obstetrical outcomes during pregnancy will be collected from the medical files. To complete data collection, a face-to-face interview with women around delivery phase will be scheduled. All relevant data such as pregnancy complications, hospitalizations, delivery characteristics (including birth weight, terms at delivery, or fetal death) will be collected.</td></tr><tr><td>At 6&#x000a0;months after delivery (T3)</td><td>Participants will be provided with a questionnaire, on which they will be asked to record all health outcomes of their infant and associated health service use.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec15"><title>Pharmaceutical aspects</title><p>Experimental drugs, azithromycin 250&#x000a0;mg oral tablets (ZITHROMAX&#x02122;) and amoxicillin 500&#x000a0;mg oral capsules (CLAMOXYL&#x02122;), will be packaged and labeled by the &#x0201c;Unit&#x000e9; d&#x02019;Expertise Pharmaceutique et Recherche Biomedicale&#x0201d; pharmaceutical unit of the Hospital Pharmacy of AP-HM and distributed to the dispensing hospital pharmacy of each investigating center. At the end of the study, used and unused treatments will be returned to the dispensing pharmacy and destroyed.</p></sec><sec id="Sec16"><title>Sample size</title><p>The sample size was calculated from the expected differential ICER per preterm birth avoided between the two groups. In accordance with Briggs [<xref ref-type="bibr" rid="CR22">22</xref>], the following hypothesis is stated: with an expected incremental rate of preterm birth of 1.3&#x000a0;% (4.3&#x000a0;% in the control group [<xref ref-type="bibr" rid="CR23">23</xref>] and 3.0&#x000a0;% in the experimental group), an expected incremental cost of 230 euros (including cost of initial and following point-of-care tests and cost of treatments for 10&#x000a0;% of the women [<xref ref-type="bibr" rid="CR24">24</xref>]), and an expected differential ICER at 22,500 euros corresponding to the avoided cost of a preterm birth before 37&#x000a0;weeks [<xref ref-type="bibr" rid="CR25">25</xref>], with an 80&#x000a0;% statistical power and a threshold for statistical significance set at a <italic>P</italic> value of 0.05, and assuming that a potential 20&#x000a0;% of patients will be lost to follow-up, these calculations showed that 6,800 patients are needed (3,400 per group). Considering the potential of inclusion of each participating center, the inclusion duration will be planned over a 12-month period. The maximal period of participation for the included women is 12&#x000a0;months.</p></sec><sec id="Sec17"><title>Statistical analysis</title><p>The data will be analyzed using SPSS version 20.0 software. Statistical significance is defined as <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. The methodology will be based on the Consolidated Standards of Reporting Trials Statement (CONSORT, <ext-link ext-link-type="uri" xlink:href="http://www.consort-statement.org/consort-statement/">http://www.consort-statement.org/consort-statement/</ext-link>) [<xref ref-type="bibr" rid="CR26">26</xref>]. The full analysis population (including all subjects who will be randomized and will be at least evaluated at baseline) will be used in the primary analysis and the per protocol population (including all subjects who will be randomized and will not have major protocol deviations) will be used in the secondary analysis to assess the reliability of the results. Finally, missing data will be handled where possible using multiple imputations, and a sensitivity analysis will be performed. No interim analysis is planned.</p><p>The normality of the parameters will be estimated using frequency histograms and the Shapiro test. In case of nonparametric distribution, the data will be log transformed to obtain a normal distribution or nonparametric bootstrapping performed for cost data. In accordance with the distribution of the parameters, the baseline parameters will be presented separately for the control group and the experimental group: mean (standard deviation) or median (interquartile range) for continuous variables, proportions for categorical variables. Then, data will be compared between the two groups using Student&#x02019;s t-test for continuous variables (durations), and chi-square or Fisher&#x02019;s exact tests for categorical variables.</p></sec><sec id="Sec18"><title>Cost-effectiveness analysis</title><p>Incremental cost-effectiveness ratios (ICER) will be used to compare the cost and effectiveness of the experimental strategy with usual care. The ICER is the ratio of the difference between groups in costs to the difference in effectiveness. The difference in effectiveness equals the number of preterm births averted and is calculated as the number of preterm births in the screening group minus the number of preterm births in the control group. Thus, the ICER provides information on the potential acceptability of the intervention for decision makers. The costs perspective taken in our economic analysis is that of the healthcare payer. The time horizon started from the first prenatal consultation before the 20&#x000a0;weeks of gestation and ended at 6-months of age or death. The healthcare costs included are those that are likely to differ across the intervention and control groups. In our study, these costs are those associated with: screening using the point-of-care procedure (quantitative molecular analysis), control vaginal swabs for positive women, antibiotic treatments, antenatal hospital admissions, physicians&#x02019; consultations, management of complications, as well as neonatal costs for full term infants and preterm infants. Unit costs for health service use will be estimated using data from the French National Hospital Database (Programme de m&#x000e9;dicalisation des syst&#x000e8;mes d&#x02019;information, PMSI) and the National Tariff. Treatment costs were obtained from the French register of pharmaceutical specialties, an online database of information on healthcare products. The cost of the POC analysis using quantitative real-time PCR (qPCR) will be calculated using micro-costing technique, which is particularly well suited to evaluating the cost of an emerging technique [<xref ref-type="bibr" rid="CR27">27</xref>]. The volume of resources used will be determined by direct observation of each stage of each testing procedure. Fixed and variable costs will be included. All resources will be valued in 2015/2016 euros, and the 12-month trial means there is no requirement to apply discounting. As the cost of preterm birth differs significantly according to the gestational age at birth [<xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>], we will attempt to address this issue by calculating an ICER for specific birth gestational ages. Probabilistic sensitivity analyses, using the non-parametric bootstrap method, will be carried out to generate mean expected ICERs and to determine whether uncertainty or variation in the data used affect the ICERs [<xref ref-type="bibr" rid="CR31">31</xref>]. In addition, cost-effectiveness acceptability curves were constructed to represent decision uncertainty surrounding cost-effectiveness estimates [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec19"><title>Ethical aspects, laws and regulations</title><p>The study will be conducted in accordance with the Helsinki declaration and the French laws and regulations (Code de la Sant&#x000e9; Publique, article L.1121-1/Loi de Sant&#x000e9; Publique n&#x000b0;2004-806 du 9 Ao&#x000fb;t 2004 relative &#x000e0; la politique de sant&#x000e9; publique et ses d&#x000e9;crets d&#x02019;application du 27 Ao&#x000fb;t 2006) and the International Conference on Harmonization (ICH) E6 Guideline for Good Clinical Practice. Regulatory monitoring will be performed by the sponsor. French ethics committee and French drug and device regulation agency approved conduct of the AuTop study at all sites (registered number respectively: Comit&#x000e9; de Protection des Personnes Sud M&#x000e9;diterran&#x000e9;e, reference number 14.026 and Agence Nationale de S&#x000e9;curit&#x000e9; du M&#x000e9;dicament, reference number 140500A-41). This trial was registered into the government clinical trials under the identifier number NCT02288832 (ClinicalTrials.gov). Written Informed consent will be obtained from all subjects before inclusion.</p></sec></sec><sec id="Sec20" sec-type="discussion"><title>Discussion</title><p>This is the first large randomized controlled trial assessing the cost-effectiveness of a screen-and-treat program of molecular flora vaginal anomalies during the first trimester in pregnant women with low risk of preterm birth. This study was designed specifically to inform healthcare decision making, in an international context where the diagnosis of BV in pregnant women and its subsequent management care are controversial [<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. Several reasons could be stressed to explain these diverging opinions.</p><p>Firstly, there was a real lack of accuracy of diagnostic tools at the time of some studies. Most of the studies cited earlier focused on the Nugent score, which has some limitations. It must be performed on a fresh swab, and any delay in transporting the swab makes the test difficult to perform, its scoring requires experienced microbiologists to ensure consistency, and some pathogens associated with BV are not identified by such a technique, in particular <italic>A. vaginae</italic> [<xref ref-type="bibr" rid="CR9">9</xref>]. Recent studies have demonstrated that molecular biology techniques have both higher sensitivity and specificity for the diagnosis of BV [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>] compared to the Nugent score and can detect several bacterial series for BV.</p><p>The second point concerns the appropriateness of antibiotic treatment [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. The nature of the antibiotics (such as metronidazole or clindamycin, pro- or prebiotics) and their modes of administration (oral versus vaginal) vary considerably between existing studies. Few studies have controlled for treatment efficacy [<xref ref-type="bibr" rid="CR38">38</xref>]. In addition, although the frequency of recurrences after antibiotic treatment is high (from 28&#x000a0;% to 50&#x000a0;%), depending on the nature of the treatment and the length of time from its intake [<xref ref-type="bibr" rid="CR39">39</xref>], most of studies did not consider this risk of recurrence. In the present project, we propose to use azithromycin because of its effectiveness on <italic>A. vaginae</italic> and <italic>G vaginalis</italic> with a lifetime that allows us to reduce the treatment duration and to increase the adherence rate [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>The third point concerns the delay between BV and treatment. In cases of late diagnosis, and therefore delayed treatment, BV has already been established and can lead to obstetrical complications involving preterm birth [<xref ref-type="bibr" rid="CR41">41</xref>]. In this present study, we have considered that the point-of-care test will be an interesting approach to minimize the feedback of the vaginal swab to the practitioner in order to rapidly prescribe the antibiotic treatment in cases where tests are positive. In our trial, the short window for providing a diagnostic result also appears essential for minimizing the number of women lost to follow-up who may benefit from an early antibiotic treatment. Indeed, this rate of &#x0201c;lost to follow-up patients&#x0201d; is important in this disease where asymptomatic disease, anxiety and low socioeconomic status are clearly identified risk factors [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Finally, the gestational age at inclusion is the greatest limitation of previous published studies. Due to the lack of data concerning the early phase of pregnancy, the authors may have underestimated the effectiveness of a universal screen-and-treat program in reducing the rate of &#x0201c;very preterm birth&#x0201d; (28 to 32&#x000a0;weeks). These subdivisions into &#x0201c;very preterm&#x0201d; and &#x0201c;moderate&#x0201d; or &#x0201c;late preterm&#x0201d; (that is, 32 to less than 37 completed weeks of gestation) are important since decreasing gestational age is associated with increasing mortality, intensity of neonatal care required, and hence increasing costs [<xref ref-type="bibr" rid="CR42">42</xref>].</p><p>The main purpose of AuTop trial is to support at a nationwide level the feasibility, acceptability, and cost-savings of a routine point-of-care molecular diagnosis at the first stage of pregnancy. Although it is well known that the consequences in terms of morbidity and mortality of preterm birth are important and entail a significant economic burden, several studies have demonstrated that a large share of the incremental cost per surviving preterm infant is represented by neonatal care [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. The average length of this neonatal care can vary from 3&#x000a0;days to 6&#x000a0;months for very preterm births (including potential immediate re-hospitalization, programmed consultations and bronchiolitis prevention measures). We then decided to focus on this time horizon for the cost-effectiveness analysis.</p><p>In Kiss et al. [<xref ref-type="bibr" rid="CR23">23</xref>], the prevalence of BV was around 7&#x000a0;% in their study population (which included women without subjective complaints, that is, contractions, vaginal bleeding, or symptoms suggestive of vaginal infection, or women with multiple pregnancies), with less than 2.3&#x000a0;% having an obstetric history at inclusion. It is well known that the ethnic origin influences the prevalence of bacterial vaginosis in pregnancy. In Kiss&#x02019;s RCT, the population was 98&#x000a0;% white ethnic origin. In our study population, we will expected less than 65&#x000a0;% for the white ethnic group, based on our previous RTC conducted in the same French centers [<xref ref-type="bibr" rid="CR11">11</xref>]. Consequently, we think that a prevalence of BV of 10&#x000a0;% in a population with or without clinical symptoms of BV and well balanced in terms of ethnic origins is not so optimistic. Our hypothesis of a decrease in the rate of preterm births from 4.3&#x000a0;% to 3.0&#x000a0;% seems to be a small expected gain in the rate of preterm births avoided. In fact, a mean difference of 1.3&#x000a0;% is actually a very large difference for pregnant women and decision makers, and should be sufficient to prevent major healthcare expenditure. Decision analysis is particularly useful when the difference in outcomes between strategies is small, and can provide insight into the costs contributing to the public decision-making process.</p><p>Given the need for scientific evidence (in terms of both efficacy and economic) regarding bacterial vaginosis screening in a population with low-risk factors for preterm birth, our analysis should be useful for clinicians and other healthcare decision makers involved in managing care of pregnant women.</p></sec><sec id="Sec21"><title>Trial status</title><p>At the time of manuscript submission, the status of the trial is yet recruiting. The inclusion of participants started in March 2015.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AAP</term><def><p>American Academy of Pediatrics</p></def></def-item><def-item><term>ACOG</term><def><p>American Congress of Obstetricians and Gynecologists</p></def></def-item><def-item><term>ANSM</term><def><p>Agence Nationale de S&#x000e9;curit&#x000e9; du M&#x000e9;dicament</p></def></def-item><def-item><term>AP-HM</term><def><p>Assistance Publique-H&#x000f4;pitaux de Marseille</p></def></def-item><def-item><term>BV</term><def><p>bacterial vaginosis</p></def></def-item><def-item><term>CDC</term><def><p>Centre for Disease and Controls</p></def></def-item><def-item><term>CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term>DNA</term><def><p>deoxyribonucleic acid</p></def></def-item><def-item><term>eCRF</term><def><p>electronic case report form</p></def></def-item><def-item><term>HAS</term><def><p>Haute Autorit&#x000e9; en Sant&#x000e9; - French National Authority for Health</p></def></def-item><def-item><term>ICER</term><def><p>incremental cost effectiveness ratio</p></def></def-item><def-item><term>ICH</term><def><p>International Conference on Harmonization</p></def></def-item><def-item><term>PCR</term><def><p>polymerase chain reaction</p></def></def-item><def-item><term>SPSS</term><def><p>Statistical Package for the Social Sciences</p></def></def-item><def-item><term>PMSI</term><def><p>Programme de m&#x000e9;dicalisation des syst&#x000e8;mes d&#x02019;information</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>FB, CF, JFC, FF, VS, DR, KB, PA and SL conceived and/or designed the study, including the power calculation. CF and JFC acquired legal authorizations. The study protocol and manuscript have been drafted by FB, CF, SL, KB and PA. All authors read and approve the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work is supported by institutional grants from the French 2013 Programme de Recherche M&#x000e9;dico-Economique (PRME). The sponsor was represented by Assistance Publique, H&#x000f4;pitaux de Marseille, France, and its role was to control the appropriateness of ethical and legal considerations. The authors are grateful to all the investigators for their participation in the study. We thank St&#x000e9;phane Honor&#x000e9; and Kahena Amichi for their participation and collaboration during the study conception.</p><sec id="FPar1"><title>Sponsor and funder</title><p><bold><italic>Trial Sponsor</italic></bold><italic>:</italic> Assistance Publique-H&#x000f4;pitaux de Marseille (AP-HM, France)</p><p><bold><italic>Sponsor&#x02019;s Reference</italic></bold><italic>:</italic> FINESS 13 07 86 49</p><p><bold><italic>Contact name</italic></bold><italic>:</italic> Kahena AMICHI</p><p><bold><italic>Address</italic></bold><italic>:</italic> Direction de la Recherche Clinique et de l&#x02019;Innovation, 80, rue Brochier, 13354 MARSEILLE Cedex 05, France.</p><p><bold><italic>Phone</italic></bold><italic>:</italic> +33(0) 491 381 966</p><p><bold><italic>Email</italic></bold><italic>:</italic> kahena.amichi@ap-hm.fr</p><p>This funding source had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data or decision to submit results.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>HL</given-names></name><name><surname>Cousens</surname><given-names>S</given-names></name><name><surname>Perin</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>S</given-names></name><name><surname>Lawn</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>2151</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60560-1</pub-id><pub-id pub-id-type="pmid">22579125</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blondel</surname><given-names>B</given-names></name><name><surname>Lelong</surname><given-names>N</given-names></name><name><surname>Kermarrec</surname><given-names>M</given-names></name><name><surname>Goffinet</surname><given-names>F</given-names></name></person-group><article-title>National Coordination Group of the National Perinatal S. Trends in perinatal health in France from 1995 to 2010. Results from the French National Perinatal Surveys</article-title><source>J Gynecol Obstet Biol Reprod (Paris)</source><year>2012</year><volume>41</volume><fpage>e1</fpage><lpage>e15</lpage><pub-id pub-id-type="doi">10.1016/j.jgyn.2012.04.014</pub-id><pub-id pub-id-type="pmid">22613118</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blencowe</surname><given-names>H</given-names></name><name><surname>Cousens</surname><given-names>S</given-names></name><name><surname>Oestergaard</surname><given-names>MZ</given-names></name><name><surname>Chou</surname><given-names>D</given-names></name><name><surname>Moller</surname><given-names>AB</given-names></name><name><surname>Narwal</surname><given-names>R</given-names></name><etal/></person-group><article-title>National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>2162</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60820-4</pub-id><pub-id pub-id-type="pmid">22682464</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>RL</given-names></name><name><surname>Culhane</surname><given-names>JF</given-names></name><name><surname>Iams</surname><given-names>JD</given-names></name><name><surname>Romero</surname><given-names>R</given-names></name></person-group><article-title>Epidemiology and causes of preterm birth</article-title><source>Lancet</source><year>2008</year><volume>371</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60074-4</pub-id><pub-id pub-id-type="pmid">18177778</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitich</surname><given-names>H</given-names></name><name><surname>Kiss</surname><given-names>H</given-names></name></person-group><article-title>Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome</article-title><source>Best Pract Res Clin Obstet Gynaecol</source><year>2007</year><volume>21</volume><fpage>375</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.bpobgyn.2006.12.005</pub-id><pub-id pub-id-type="pmid">17241817</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>JP</given-names></name><name><surname>Mazouni</surname><given-names>C</given-names></name><name><surname>Fenollar</surname><given-names>F</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name><name><surname>Boubli</surname><given-names>L</given-names></name><name><surname>Bretelle</surname><given-names>F</given-names></name></person-group><article-title>Diagnostic accuracy of quantitative real-time PCR assay versus clinical and Gram stain identification of bacterial vaginosis</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2010</year><volume>29</volume><fpage>1547</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s10096-010-1039-3</pub-id><pub-id pub-id-type="pmid">20814710</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cartwright</surname><given-names>CP</given-names></name><name><surname>Lembke</surname><given-names>BD</given-names></name><name><surname>Ramachandran</surname><given-names>K</given-names></name><name><surname>Body</surname><given-names>BA</given-names></name><name><surname>Nye</surname><given-names>MB</given-names></name><name><surname>Rivers</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Development and validation of a semiquantitative, multitarget PCR assay for diagnosis of bacterial vaginosis</article-title><source>J Clin Microbiol</source><year>2012</year><volume>50</volume><fpage>2321</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1128/JCM.00506-12</pub-id><pub-id pub-id-type="pmid">22535982</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marconi</surname><given-names>C</given-names></name><name><surname>Cruciani</surname><given-names>F</given-names></name><name><surname>Vitali</surname><given-names>B</given-names></name><name><surname>Donders</surname><given-names>GG</given-names></name></person-group><article-title>Correlation of Atopobium vaginae amount with bacterial vaginosis markers</article-title><source>J Low Genit Tract Dis</source><year>2012</year><volume>16</volume><fpage>127</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/LGT.0b013e31823c79c4</pub-id><pub-id pub-id-type="pmid">22371042</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>JP</given-names></name><name><surname>Fenollar</surname><given-names>F</given-names></name><name><surname>Henry</surname><given-names>M</given-names></name><name><surname>Bretelle</surname><given-names>F</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name></person-group><article-title>Molecular quantification of Gardnerella vaginalis and Atopobium vaginae loads to predict bacterial vaginosis</article-title><source>Clin Infect Dis</source><year>2008</year><volume>47</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1086/588661</pub-id><pub-id pub-id-type="pmid">18513147</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>JP</given-names></name><name><surname>Mazouni</surname><given-names>C</given-names></name><name><surname>Salem-Cherif</surname><given-names>I</given-names></name><name><surname>Fenollar</surname><given-names>F</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name><name><surname>Boubli</surname><given-names>L</given-names></name><etal/></person-group><article-title>High vaginal concentrations of Atopobium vaginae and Gardnerella vaginalis in women undergoing preterm labor</article-title><source>Obstet Gynecol</source><year>2010</year><volume>115</volume><fpage>134</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1097/AOG.0b013e3181c391d7</pub-id><pub-id pub-id-type="pmid">20027045</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bretelle</surname><given-names>F</given-names></name><name><surname>Rozenberg</surname><given-names>P</given-names></name><name><surname>Pascal</surname><given-names>A</given-names></name><name><surname>Favre</surname><given-names>R</given-names></name><name><surname>Bohec</surname><given-names>C</given-names></name><name><surname>Loundou</surname><given-names>A</given-names></name><etal/></person-group><article-title>High Atopobium vaginae and Gardnerella vaginalis Vaginal Loads are associated with preterm birth</article-title><source>Clin Infect Dis</source><year>2015</year><volume>60</volume><fpage>860</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu966</pub-id><pub-id pub-id-type="pmid">25452591</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">HAS. Pr&#x000e9;vention ant&#x000e9;natale du risque infectieux bact&#x000e9;rien n&#x000e9;onatal pr&#x000e9;coce: recommandations, Septembre 2001. In: Servoces recommandations et r&#x000e9;f&#x000e9;rences professionnelles. 2001. <ext-link ext-link-type="uri" xlink:href="http://www.has-sante.fr/portail/upload/docs/application/pdf/prevention_antenatale_du_risque_infectieux_bacterien_-_rec.pdf">http://www.has-sante.fr/portail/upload/docs/application/pdf/prevention_antenatale_du_risque_infectieux_bacterien_-_rec.pdf</ext-link>. Accessed 15 April 2015.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines, 2010. In: Recommendations and Reports. 2010. <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/std/treatment/2010/std-treatment-2010-rr5912.pdf">http://www.cdc.gov/std/treatment/2010/std-treatment-2010-rr5912.pdf</ext-link>. Accessed 15 April 2015.</mixed-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joesoef</surname><given-names>MR</given-names></name><name><surname>Schmid</surname><given-names>G</given-names></name></person-group><article-title>Bacterial vaginosis</article-title><source>Clin Evid</source><year>2005</year><volume>13</volume><fpage>1968</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">16135317</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredricks</surname><given-names>DN</given-names></name><name><surname>Fiedler</surname><given-names>TL</given-names></name><name><surname>Marrazzo</surname><given-names>JM</given-names></name></person-group><article-title>Molecular identification of bacteria associated with bacterial vaginosis</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>1899</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043802</pub-id><pub-id pub-id-type="pmid">16267321</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shipitsyna</surname><given-names>E</given-names></name><name><surname>Roos</surname><given-names>A</given-names></name><name><surname>Datcu</surname><given-names>R</given-names></name><name><surname>Hallen</surname><given-names>A</given-names></name><name><surname>Fredlund</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Composition of the vaginal microbiota in women of reproductive age--sensitive and specific molecular diagnosis of bacterial vaginosis is possible?</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e60670</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0060670</pub-id><pub-id pub-id-type="pmid">23585843</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>JP</given-names></name><name><surname>Fenollar</surname><given-names>F</given-names></name><name><surname>Raoult</surname><given-names>D</given-names></name><name><surname>Boubli</surname><given-names>L</given-names></name><name><surname>Bretelle</surname><given-names>F</given-names></name></person-group><article-title>Self-collected vaginal swabs for the quantitative real-time polymerase chain reaction assay of Atopobium vaginae and Gardnerella vaginalis and the diagnosis of bacterial vaginosis</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2012</year><volume>31</volume><fpage>513</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s10096-011-1341-8</pub-id><pub-id pub-id-type="pmid">21789604</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname><given-names>H</given-names></name><name><surname>Pichler</surname><given-names>E</given-names></name><name><surname>Petricevic</surname><given-names>L</given-names></name><name><surname>Husslein</surname><given-names>P</given-names></name></person-group><article-title>Cost effectiveness of a screen-and-treat program for asymptomatic vaginal infections in pregnancy: towards a significant reduction in the costs of prematurity</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2006</year><volume>127</volume><fpage>198</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2005.10.017</pub-id><pub-id pub-id-type="pmid">16303228</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>AAA, ACOG</collab></person-group><source>Guidelines for perinatal care. American Academy of Pediatrics. American College of Obstetricians and Gynecologists</source><year>2012</year><edition>7</edition><publisher-loc>Washington, DC</publisher-loc><publisher-name>Elk Grove Village (IL)</publisher-name></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beaino</surname><given-names>G</given-names></name><name><surname>Khoshnood</surname><given-names>B</given-names></name><name><surname>Kaminski</surname><given-names>M</given-names></name><name><surname>Marret</surname><given-names>S</given-names></name><name><surname>Pierrat</surname><given-names>V</given-names></name><name><surname>Vieux</surname><given-names>R</given-names></name><etal/></person-group><article-title>Predictors of the risk of cognitive deficiency in very preterm infants: the EPIPAGE prospective cohort</article-title><source>Acta Paediatr</source><year>2011</year><volume>100</volume><fpage>370</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1651-2227.2010.02064.x</pub-id><pub-id pub-id-type="pmid">21241364</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berbis</surname><given-names>J</given-names></name><name><surname>Einaudi</surname><given-names>MA</given-names></name><name><surname>Simeoni</surname><given-names>MC</given-names></name><name><surname>Brevaut-Malaty</surname><given-names>V</given-names></name><name><surname>Auquier</surname><given-names>P</given-names></name><name><surname>d'Ercole</surname><given-names>C</given-names></name><etal/></person-group><article-title>Quality of life of early school-age French children born preterm: a cohort study</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2012</year><volume>162</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2012.02.006</pub-id><pub-id pub-id-type="pmid">22424585</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Gray</surname><given-names>AM</given-names></name></person-group><article-title>Power and sample size calculations for stochastic cost-effectiveness analysis</article-title><source>Med Decis Making</source><year>1998</year><volume>18</volume><issue>2 Suppl</issue><fpage>S81</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1177/0272989X9801800210</pub-id><pub-id pub-id-type="pmid">9566469</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss</surname><given-names>H</given-names></name><name><surname>Petricevic</surname><given-names>L</given-names></name><name><surname>Husslein</surname><given-names>P</given-names></name></person-group><article-title>Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery</article-title><source>BMJ</source><year>2004</year><volume>329</volume><fpage>371</fpage><pub-id pub-id-type="doi">10.1136/bmj.38169.519653.EB</pub-id><pub-id pub-id-type="pmid">15294856</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goffinet</surname><given-names>F</given-names></name><name><surname>Maillard</surname><given-names>F</given-names></name><name><surname>Mihoubi</surname><given-names>N</given-names></name><name><surname>Kayem</surname><given-names>G</given-names></name><name><surname>Papiernik</surname><given-names>E</given-names></name><name><surname>Cabrol</surname><given-names>D</given-names></name><etal/></person-group><article-title>Bacterial vaginosis: prevalence and predictive value for premature delivery and neonatal infection in women with preterm labour and intact membranes</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2003</year><volume>108</volume><fpage>146</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0301-2115(02)00423-2</pub-id><pub-id pub-id-type="pmid">12781402</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrou</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>K</given-names></name></person-group><article-title>Economic costs associated with moderate and late preterm birth: primary and secondary evidence</article-title><source>Semin Fetal Neonatal Med</source><year>2012</year><volume>17</volume><fpage>170</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.siny.2012.02.001</pub-id><pub-id pub-id-type="pmid">22364679</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Group</surname><given-names>C</given-names></name></person-group><article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title><source>Trials</source><year>2010</year><volume>11</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-11-32</pub-id><pub-id pub-id-type="pmid">20334632</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clements</surname><given-names>KM</given-names></name><name><surname>Barfield</surname><given-names>WD</given-names></name><name><surname>Ayadi</surname><given-names>MF</given-names></name><name><surname>Wilber</surname><given-names>N</given-names></name></person-group><article-title>Preterm birth-associated cost of early intervention services: an analysis by gestational age</article-title><source>Pediatrics</source><year>2007</year><volume>119</volume><fpage>e866</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1542/peds.2006-1729</pub-id><pub-id pub-id-type="pmid">17339387</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>RB</given-names></name><name><surname>Green</surname><given-names>NS</given-names></name><name><surname>Steiner</surname><given-names>CA</given-names></name><name><surname>Meikle</surname><given-names>S</given-names></name><name><surname>Howse</surname><given-names>JL</given-names></name><name><surname>Poschman</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cost of hospitalization for preterm and low birth weight infants in the United States</article-title><source>Pediatrics</source><year>2007</year><volume>120</volume><fpage>e1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1542/peds.2006-2386</pub-id><pub-id pub-id-type="pmid">17606536</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrou</surname><given-names>S</given-names></name></person-group><article-title>The economic consequences of preterm birth during the first 10&#x000a0;years of life</article-title><source>BJOG</source><year>2005</year><volume>112</volume><issue>Suppl 1</issue><fpage>10</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.2005.00577.x</pub-id><pub-id pub-id-type="pmid">15715587</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>AH</given-names></name></person-group><article-title>Statistical approaches to handling uncertainty in health economic evaluation</article-title><source>Eur J Gastroenterol Hepatol</source><year>2004</year><volume>16</volume><fpage>551</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1097/00042737-200406000-00007</pub-id><pub-id pub-id-type="pmid">15167156</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fenwick</surname><given-names>E</given-names></name><name><surname>Claxton</surname><given-names>K</given-names></name><name><surname>Sculpher</surname><given-names>M</given-names></name></person-group><article-title>Representing uncertainty: the role of cost-effectiveness acceptability curves</article-title><source>Health Econ</source><year>2001</year><volume>10</volume><fpage>779</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1002/hec.635</pub-id><pub-id pub-id-type="pmid">11747057</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brocklehurst</surname><given-names>P</given-names></name><name><surname>Gordon</surname><given-names>A</given-names></name><name><surname>Heatley</surname><given-names>E</given-names></name><name><surname>Milan</surname><given-names>SJ</given-names></name></person-group><article-title>Antibiotics for treating bacterial vaginosis in pregnancy</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>1</volume><fpage>CD000262</fpage><pub-id pub-id-type="pmid">23440777</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okun</surname><given-names>N</given-names></name><name><surname>Gronau</surname><given-names>KA</given-names></name><name><surname>Hannah</surname><given-names>ME</given-names></name></person-group><article-title>Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy: a systematic review</article-title><source>Obstet Gynecol</source><year>2005</year><volume>105</volume><fpage>857</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1097/01.AOG.0000157108.32059.8f</pub-id><pub-id pub-id-type="pmid">15802417</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nygren</surname><given-names>P</given-names></name><name><surname>Fu</surname><given-names>R</given-names></name><name><surname>Freeman</surname><given-names>M</given-names></name><name><surname>Bougatsos</surname><given-names>C</given-names></name><name><surname>Klebanoff</surname><given-names>M</given-names></name><name><surname>Guise</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventive Services Task Force</article-title><source>Ann Intern Med</source><year>2008</year><volume>148</volume><fpage>220</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-148-3-200802050-00008</pub-id><pub-id pub-id-type="pmid">18252684</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamont</surname><given-names>RF</given-names></name><name><surname>Taylor-Robinson</surname><given-names>D</given-names></name></person-group><article-title>Review of the accuracy of various diagnostic tests for bacterial vaginosis to predict preterm birth (Honest et al., BJOG, May 2004)</article-title><source>BJOG</source><year>2005</year><volume>112</volume><fpage>259</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.2005.00241.x</pub-id><pub-id pub-id-type="pmid">15663596</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGregor</surname><given-names>JA</given-names></name><name><surname>French</surname><given-names>JI</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name><name><surname>Draper</surname><given-names>D</given-names></name><name><surname>Patterson</surname><given-names>E</given-names></name><name><surname>Jones</surname><given-names>W</given-names></name><etal/></person-group><article-title>Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation</article-title><source>Am J Obstet Gynecol</source><year>1995</year><volume>173</volume><fpage>157</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/0002-9378(95)90184-1</pub-id><pub-id pub-id-type="pmid">7631673</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menard</surname><given-names>JP</given-names></name><name><surname>Bretelle</surname><given-names>F</given-names></name></person-group><article-title>How can the treatment of bacterial vaginosis be improved to reduce the risk of preterm delivery?</article-title><source>Womens Health (Lond Engl)</source><year>2012</year><volume>8</volume><fpage>491</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.2217/whe.12.32</pub-id><pub-id pub-id-type="pmid">22934721</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradshaw</surname><given-names>CS</given-names></name><name><surname>Morton</surname><given-names>AN</given-names></name><name><surname>Hocking</surname><given-names>J</given-names></name><name><surname>Garland</surname><given-names>SM</given-names></name><name><surname>Morris</surname><given-names>MB</given-names></name><name><surname>Moss</surname><given-names>LM</given-names></name><etal/></person-group><article-title>High recurrence rates of bacterial vaginosis over the course of 12&#x000a0;months after oral metronidazole therapy and factors associated with recurrence</article-title><source>J Infect Dis</source><year>2006</year><volume>193</volume><fpage>1478</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1086/503780</pub-id><pub-id pub-id-type="pmid">16652274</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Backer</surname><given-names>E</given-names></name><name><surname>Verhelst</surname><given-names>R</given-names></name><name><surname>Verstraelen</surname><given-names>H</given-names></name><name><surname>Claeys</surname><given-names>G</given-names></name><name><surname>Verschraegen</surname><given-names>G</given-names></name><name><surname>Temmerman</surname><given-names>M</given-names></name><etal/></person-group><article-title>Antibiotic susceptibility of Atopobium vaginae</article-title><source>BMC Infect Dis</source><year>2006</year><volume>6</volume><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-6-51</pub-id><pub-id pub-id-type="pmid">16542416</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svare</surname><given-names>JA</given-names></name><name><surname>Schmidt</surname><given-names>H</given-names></name><name><surname>Hansen</surname><given-names>BB</given-names></name><name><surname>Lose</surname><given-names>G</given-names></name></person-group><article-title>Bacterial vaginosis in a cohort of Danish pregnant women: prevalence and relationship with preterm delivery, low birthweight and perinatal infections</article-title><source>BJOG</source><year>2006</year><volume>113</volume><fpage>1419</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.2006.01087.x</pub-id><pub-id pub-id-type="pmid">17010117</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Behrman RE, Butler AS. Preterm birth: causes, consequences, and prevention. Washington (DC): National Academies Press (US); 2007.</mixed-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangham</surname><given-names>LJ</given-names></name><name><surname>Petrou</surname><given-names>S</given-names></name><name><surname>Doyle</surname><given-names>LW</given-names></name><name><surname>Draper</surname><given-names>ES</given-names></name><name><surname>Marlow</surname><given-names>N</given-names></name></person-group><article-title>The cost of preterm birth throughout childhood in England and Wales</article-title><source>Pediatrics</source><year>2009</year><volume>123</volume><fpage>e312</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1542/peds.2008-1827</pub-id><pub-id pub-id-type="pmid">19171583</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korvenranta</surname><given-names>E</given-names></name><name><surname>Lehtonen</surname><given-names>L</given-names></name><name><surname>Rautava</surname><given-names>L</given-names></name><name><surname>Hakkinen</surname><given-names>U</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Gissler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impact of very preterm birth on health care costs at five years of age</article-title><source>Pediatrics</source><year>2010</year><volume>125</volume><fpage>e1109</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1542/peds.2009-2882</pub-id><pub-id pub-id-type="pmid">20368320</pub-id></element-citation></ref></ref-list></back></article>